levetiracetam
Drug Details
- Generic Name
- levetiracetam
- Brand Names
- levetiracetam, Levetiracetam, Levetiracetam Extended-Release, Keppra XR, LEVETIRACETAM, Keppra, Spritam, ELEPSIA XR 1500 MG, ELEPSIA XR 1000 MG
- Application Number
- ANDA206880
- Sponsor
- Sagent Pharmaceuticals
- NDC Codes
- 50
- Dosage Forms
- INJECTION, SOLUTION, INJECTION, TABLET, FILM COATED, POWDER, TABLET, FILM COATED, EXTENDED RELEASE, SOLUTION, INJECTION, SOLUTION, CONCENTRATE, TABLET, FOR SUSPENSION, TABLET, EXTENDED RELEASE
- Routes
- INTRAVENOUS, ORAL
- Active Ingredients
- LEVETIRACETAM
Indications and Usage
1 INDICATIONS AND USAGE Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.